Document Detail


A randomized trial of antithrombin concentrate for treatment of heparin resistance.
MedLine Citation:
PMID:  11016326     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Heparin resistance is an important clinical problem traditionally treated with additional heparin or fresh frozen plasma. We undertook a randomized clinical trial to determine if treatment with antithrombin (AT) concentrate is effective for treating this condition. METHODS: Patients requiring cardiopulmonary bypass who were considered to be heparin resistant (activated clotting time < 480 seconds after > 450 IU/kg heparin) were randomized to receive either 1000 U AT or additional heparin. RESULTS: AT concentrate was effective in 42 of 44 patients (96%) for immediately obtaining a therapeutic activated clotting time. This compared favorably to 28 of 41 patients (68%) treated with additional heparin (p = 0.001). All patients who failed heparin therapy were successfully treated with AT. The patients receiving AT required less time to obtain an adequate ACT but there was no difference in clinical outcomes among the groups. Study patients had deficient AT activity at baseline (56%+/-25%), which improved in those given AT concentrate (75%+/-31% versus 50%+/-23%, p < 0.0005). CONCLUSIONS: Heparin resistance is frequently associated with AT deficiency. Treating this deficiency with AT concentrate is more effective and faster for obtaining adequate anticoagulation than using additional heparin.
Authors:
M R Williams; A B D'Ambra; J R Beck; T B Spanier; D L Morales; D N Helman; M C Oz
Related Documents :
11112236 - Clinical risk factors and timing of recurrent venous thromboembolism during the initial...
22683986 - Comparison of the application of allogeneic fibroblast and autologous mesh grafting wit...
11856686 - Using a peptide inhibitor of the glycoprotein iib/iiia platelet receptor: initial exper...
11451826 - Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular di...
11106526 - The effectiveness of adcon-t/n, a new anti-adhesion barrier gel, in fresh divisions of ...
3044086 - Double-blind, placebo-controlled trial comparing long-term suppressive with short-term ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  70     ISSN:  0003-4975     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2000 Sep 
Date Detail:
Created Date:  2000-10-17     Completed Date:  2000-10-17     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  873-7     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA. mw365@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antithrombins / administration & dosage,  analysis,  therapeutic use*
Blood Coagulation Tests
Cardiopulmonary Bypass
Drug Resistance
Female
Heparin / administration & dosage,  pharmacology*
Humans
Male
Middle Aged
Thrombin / analysis
Grant Support
ID/Acronym/Agency:
T32-HL07343/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antithrombins; 9005-49-6/Heparin; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from P...
Next Document:  Improvement by phosphoramidon of damaged endothelial function in porcine coronary artery.